Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, vaccines and immunoinformatics approaches, and CAR-T cell therapy research.
Biodegradable Carbonate Nanogels Loaded with Anti MFAP‐5 siRNA for Anti‐stromal Therapy of Hepatocellular Carcinoma
Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer‐Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma
A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing
MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
Carbon Ion and Photon Radiation Therapy Show Enhanced Antitumoral Therapeutic Efficacy With Neoantigen RNA-LPX Vaccines in Preclinical Colon Carcinoma Models
CoVigator—A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants
Identification of neoantigens for individualized therapeutic cancer vaccines
Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates
NeoFox: annotating neoantigen candidates with neoantigen features
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Bioinformatics for Cancer Immunotherapy
A liposomal RNA vaccine inducing neoantigen-specific CD4 <sup>+</sup> T cells augments the antitumor activity of local radiotherapy in mice
Challenges towards the realization of individualized cancer vaccines
Evolution of melanoma cross-resistance to CD8<sup>+</sup> T cells and MAPK inhibition in the course of BRAFi treatment
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination